CDKN2A and glioma: There are three published GWAS to date that have identified eight different loci associated with glioma risk [1], [2], [3], including variants annotating key genes in glioma progression, such as the epidermal growth factor receptor (EGFR), and the tumor suppressor gene CDKN2A (alias p14, p16, and ARF).